Desipramine in Infantile Neuroaxonal Dystrophy (INAD).
|ClinicalTrials.gov Identifier: NCT03726996|
Recruitment Status : Enrolling by invitation
First Posted : November 1, 2018
Last Update Posted : January 16, 2019
This is a research study to find out if clinically prescribed desipramine is effective at improving the symptoms and slowing the progression of Infantile Neuroaxonal Dystrophy (INAD) in affected children.
Participants will receive an initial oral dose of study drug once a day. This dose may be changed depending on response to study drug Clinically collected data will be recorded for up to 5 years. Investigators will also ask for participant permission to obtain a sample of child's skin biopsy from unused clinical sample previously collected for standard of care.
|Condition or disease||Intervention/treatment||Phase|
|Infantile Neuroaxonal Dystrophy||Drug: Desipramine||Phase 4|
To be eligible participants must be able to swallow tablets The study drug is to be taken once daily Schedule of events. Day 0 - ECG and blood tests (4 ml or ¾ teaspoon) Day 3 - ECG and blood tests (4 ml or ¾ teaspoon) Day 7 - ECG and blood tests (4 ml or ¾ teaspoon) Weeks 2, 3, 4, 8 & 12. ECG and blood tests (4 ml or ¾ teaspoon) Every 3 months for up to 5 years.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||3 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Novel Off-label Use of Desipramine in Infantile Neuroaxonal Dystrophy: Targeting the Sphingolipid Metabolism Pathway to Reduce Accumulation of Ceramide.|
|Actual Study Start Date :||January 14, 2019|
|Estimated Primary Completion Date :||November 30, 2020|
|Estimated Study Completion Date :||November 30, 2020|
Experimental: Children with INAD
Infantile neuroaxonal dystrophy (INAD) is an extremely rare autosomal recessive neurodegenerative disorder that has grave clinical outcome and significant morbidity and mortality.
Study drug (desipramine) provided in tablet form to be taken daily.
- Change in gross motor function as measured by Gross Motor Function Measure (GMFM) [ Time Frame: Baseline, 3 months, 6 months, 9 months & 12 months. ]
The Gross Motor Function Measure (GMFM) is a 66 item standardized observational instrument designed and validated to measure change in gross motor function over time in children with cerebral palsy. Items are ordered in terms of difficulty and a unit of change has the same meaning throughout the scale ranging from 0 to 100.
SCORING KEY 0 = does not initiate
- = initiates
- = partially completes
- = completes
- Change in motor function as measured by Quick Motor Function Test (QMFT) [ Time Frame: Baseline, 3 months, 6 months 9 months & 12 months ]The Quick Motor Function Test (QMFT) is a 16 item, psychometrically robust outcome assessment, validated in children and adults with Pompe disease (a lysosomal storage disorder characterized by progressive muscle weakness). This motor function test observes performance and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). If items can be performed on both left and right extremities, the right side is taken. A total score is obtained by adding the scores of all items. The total score ranges between 0 and 64 points. A high score correlates with greater motor function.
- Change in cognitive function as measured by the Vineland Adaptive Behavioral Scale [ Time Frame: Baseline, 3 months, 6 months, 9 months & 12 months ]The Vineland-3 is a standardized measure of adaptive behavior--the things that people do to function in their everyday lives. It is a norm-based instrument that compares the examinee's adaptive functioning in four domains: Communication, Daily Living Skills, Socialization and Motor Skills to that of others of the same age. A composite score of adaptive behavior is calculated that summarizes the individual's performance across all four domains.
- Number of Participants with Change in Q-T interval on ECG. [ Time Frame: Baseline, 3 months, 6 months, 9 months & 12 months ]Evidence of ECG changes, specifically, prolonged Q-T interval in response to study drug.
- Number of Participants With Abnormal Transaminase Values [ Time Frame: Baseline, 3 months, 6 months, 9 months & 12 months ]Change in transaminase values as measured by serum alanine transaminase (ALT) and aspartate transaminase (AST)
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03726996
|United States, North Carolina|
|Duke University Health Center|
|Durham, North Carolina, United States, 27710|
|Principal Investigator:||Yong-hui Jiang, MD||Duke University|